Warning letters, 483s, Recalls, Import Alerts, Audit observations
USFDA 483 to Lupin Pithampur in Mar 2023 (Inspectors Eileen A Liu, Yvins Dezan) cites deficiencies in Training Management, Defining responsibilities of Quality unit, Change Management, Quality Agreement with suppliers
Observation 4
Employees engaged in the manufacture processing, packing and holding of a drug product lack the training required to perform their assigned functions.
Firm failed to monitor and ensure that personnel complete their assigned training by the due date. Training is assigned in SABA software (which was validated in 2011) and Firm do not assign the due dates in SABA. Firm failed to provide an ongoing CGMP training to contracted personnel.
Observation 5
The responsibilities and procedures applicable to the quality control unit are not [in writing], [fully followed]. Specifically,
A. Firm failed to adequately classify and assess Change Control #CCP-MM-941-21-00030003 initiated on January 14, 2023 for upgrading the Windows operating system from 2008 to 2016. Firm classified the change as “Minor” where revalidation is required and did not perform an assessment of the change.
B. Firm has not established quality agreements with specific suppliers for excipients.
Training:
JD – > Skills required – >Trainings required (SOPs, other Technical trainings)
Change control systems:
Change Management procedure and process should consider the potential impact due to changes and accordingly consider level of change actions. The Change control documentation (form) should identify:1) Change (existing system and proposed system), 2) Rationale for Change (why change is required).
Many a time rationale for change only document that change will not have an impact on the system /procedure/ product; but fail to recognize why the change itself is required – is it going to simply the process / operation; improve the quality of product – process, improve efficiency. This should be adequately documented
The classification of the change (Major/Minor) should be commensurate with the impact / risk on the system, procedure, product. The Change categorization as Major / Minor guides the extent of actions for implementing the change (Validation, Qualification, Updating Regulatory agencies, customers etc). Obviously, the extent of actions to implement the change will be less when the change classification is minor. But the rationale for classifying a change as Major / Minor should be sound – avoid the temptation to classify the change as minor, so that the change implementation actions are minimal. The Change control documentation should also document the rationale for classification as Major/Minor; this will help in avoiding the pitfall of classifying a Major change as Minor.
Changes such as change to Computer systems, Operating systems should evaluate the impact in detail – Is the change impacting any GxP system, with a comprehensive list of systems that will be impacted by the change identifying whether the system is GxP or not. This will help in concluding the impact of change and extent of change implementation actions to be performed. For example, if a change like upgradation of Windows operating system is limited to computer systems used for documentation and communication, it may not have a GxP impact and no validation is necessary; a verification of systems to check whether each system is upgraded is sufficient and the change could be classified Minor. But if this change is also going to have an impact on GxP systems / computers connected to GxP systems (for example – Computer systems connected to analytical instruments or a QMS system), change category become Major, Validation / Qualification will be necessary to implement the change. The rationale should be well documented.
Companies should have Quality agreements with suppliers of all key input materials, including excipient. This should be part of the Vendor Qualification and approval process. As per Pharma GMP requirements excipients also should comply to applicable GMP; the Quality agreement shall elaborate the commitments, controls and procedures from the excipient vendors. Addition of new excipients / excipient vendors shall be handled through the Change control procedure, and Establishing Quality agreement should be one of the change actions to be completed while introducing a new vendor / new excipient.
Leave a Comment
You must be logged in to post a comment.